Adherence issues to antipsychotic medication in schizophrenia: results from a Hong Kong survey targeted for psychiatrists and case managers
DOI:
https://doi.org/10.61841/pevvmv08Keywords:
Schizophrenia,, adherence,, antipsychotics,, psychiatrists,, survey,, Hong KongAbstract
Objective: The overall level of adherence of Hong Kong patients with schizophrenia is relatively unknown, and this report therefore aims to investigate the attitude of local patients towards antipsychotics, to hopefully assist future development of
potential strategies to address adherence problems.
Methods: A survey consisting of adherence-related questions in schizophrenia was given to 71 psychiatrists and 143 case managers in Hong Kong. Survey results were summarised descriptively, and percentages for each multiple choice answer picked for each question were calculated.
Results: Over half of the surveyees estimated that their patients were either partially or non-adherent with their anti- psychotic medication during the past month. The three major barriers to patient recovery and improved functioning were “medication non-adherence” (93%), followed by “loss of insight into illness” (85%), and “lack of integrated psychosocial support” (45%). A large proportion of patients did not understand the risk of relapse due to non-adherence and showed lack of insight into illness.
Conclusion: Our findings provide a glimpse of the adherence issues and perceptions of local healthcare providers regard- ing medication taking behaviours of local patients with schizophrenia. Further studies are required to examine the factors behind treatment non-adherence.
Downloads
References
Aldebot, S., & Weisman, de Mamani A. (2009). Denial and acceptance coping styles and medication adherence in schizo- phrenia. Journal of Nervous and Mental Disease, 197, 580-584.
Barkhof, E., Meijer, C.J., de Sonneville, L.M., Linszen, D.H., & de Haan, L. (2012). Interventions to improve adherence to antipsychotic medication in patients with schizophrenia--a review of the past decade. European Psychiatry, 27, 9-18.
Birnbaum, M., & Sharif, Z. (2008). Medication adherence in schizophrenia: patient perspectives and the clinical utility of paliperidone ER. Patient Preference and Adherence, 2, 233-240.
Chakraborty, K., & Basu, D. (2010). Insight in schizophrenia – a comprehensive update. German Journal of Psychiatry, 13, 17-30.
Dilla, T., Ciudad, A., & Álvarez, M. (2013). Systematic review of the economic aspects of nonadherence to antipsychotic medication in patients with schizophrenia. Patient Preference and Adherence, 7, 275-284.
Freudenreich, O., & Cather, C. (2012). Antipsychotic medication nonadherence: risk factors and remedies. Focus (Other), X(2), 124-129.
Gibson, S., Brand, S.L., Burt, S., Boden, Z.V.R., & Benson, O. (2013). Understanding treatment non-adherence in schizo- phrenia and bipolar disorder: a survey of what service users do and why. BMC Psychiatry, 13, 153.
Higashi, K., Medic, G., Littlewood, K.J., Diez, T., Granström, O., & De Hert, M. (2013). Medication adherence in schizo- phrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Therapeutic Ad- vances in Psychopharmacology, 3, 200-218.
Johansen, R., Iversen, V.C., Melle, I., & Hestad, K.A. (2013). Therapeutic alliance in early schizophrenia spectrum dis- orders: a cross-sectional study. Annals of General Psychiatry, 12, 14.
Kaplan, G., Casoy, J., & Zummo, J. (2013). Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. Patient Preference and Adherence, 7, 1171-1180.
Masand, P.S., Roca, M., Turner, M.S., & Kane, J.M. (2009). Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review. Primary Care Companion to The Journal of Clinical Psychiatry, 11, 147-154.
Munro, J., Osborne, S., Dearden, L., Pascoe, K., Gauthier, A., & Price, M. (2011). Hospital treatment and management in relapse of schizophrenia in the UK: associated costs. Psychiatric Bulletin, 35, 95-100.
Olivares, J.M., Thirunavukarasu, M., Kulkarni, J., Zhang, H.Y., Zhang, M., & Zhang, F. (2013). Psychiatrists’ awareness of partial and nonadherence to antipsychotic medication in schizophrenia: results from an Asia-Pacific survey. Neuropsy- chiatric Disease and Treatment, 9, 1163-1170.
Penn, D.L., Mueser, K.T., Tarrier, N., Gloege, A., Cather, C., Serrano, D., & Otto, M.W. (2004). Supportive therapy for schizophrenia: possible mechanisms and implications for adjunctive psychosocial treatments. Schizophrenia Bulletin, 30, 101-112.
Potkin, S., Bera, R., Zubek, D., & Lau, G. (2013). Patient and prescriber perspectives on long-acting injectable (LAI) anti- psychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia. BMC Psychiatry, 13, 261.
Shuler, K.M. (2014). Approaches to improve adherence to pharmacotherapy in patients with schizophrenia. Patient Prefer- ence and Adherence, 8, 701-714.
Smeraldi, E., Cavallaro, R., Folnegovic-Šmalc, V., Bidzan, L., Ceylan, M.E., & Schreiner, A. (2013). Long-term remission
in schizophrenia and schizoaffective disorder: results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Therapeutic Advances in Psychopharmacology, 3, 191-199.
Velligan, D.I., Lam, Y.W., Glahn, D.C., Barrett, J.A., Maples, N.J., Ereshefsky, L., & Miller, A.L. (2006). Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophrenia Bulletin, 32, 724-742.
Velligan, D.I., Weiden, P.J., Sajatovic, M., Scott, J., Carpenter, D., Ross, R., Docherty, J.P.; Expert Consensus Panel on Adherence Problems in Serious and Persistent Mental Illness. (2009). The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. Journal of Clinical Psychiatry, 70 Suppl 4, 1-46.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
